NCT00530946View on ClinicalTrials.gov

A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin

PHASE3CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
HypertensionHypercholesterolemia
Interventions
DRUG

Amlodipine 2.5mg/Atorvastatin 5mg

Single pill combination, dosed once daily for 8 weeks

DRUG

Amlodipine 2.5mg/Atorvastatin 10mg

Single pill combination, dosed once daily for 8 weeks

DRUG

Amlodipine 5mg/Atorvastatin 5mg

Single pill combination, dosed once daily for 8 weeks

DRUG

Amlodipine 5mg/Atorvastatin 10mg

Single pill combination, dosed once daily for 8 weeks

Trial Locations (17)

Unknown

Pfizer Investigational Site, Fukuoka

Pfizer Investigational Site, Kitakyushu-shi

Pfizer Investigational Site, Kurume-shi

Pfizer Investigational Site, Maebaru-shi

Pfizer Investigational Site, Annaka

Pfizer Investigational Site, Sapporo

Pfizer Investigational Site, Teine

Pfizer Investigational Site, Yokohama

Pfizer Investigational Site, Yamashitachō

Pfizer Investigational Site, Kita-ku

Pfizer Investigational Site, Koshigaya-shi

Pfizer Investigational Site, Chōfu

Pfizer Investigational Site, Kiyose

Pfizer Investigational Site, Setagaya-ku

Pfizer Investigational Site, Shinagawa-Ku

Pfizer Investigational Site, Shinagawa

Pfizer Investigational Site, Osaka

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00530946 - A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin | Biotech Hunter | Biotech Hunter